Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06033222 · ClinicalTrials.gov registry record · Early Phase 1
A Study of Perturbation of Human Small Intestinal Colonic Permeability
A Early Phase 1 study of Healthy, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06033222: Completed Early Phase 1 study of Healthy, sponsored by Mayo Clinic.
NCT06033222 is a Early Phase 1 study of Healthy that has completed, run by Mayo Clinic. The registered enrollment target is 24 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06033222, a Early Phase 1 study of Healthy, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect of castor oil versus placebo on intestinal permeability in healthy individuals.
Primary Outcome
Percent urinary excretion of 13\^C-mannitol
Conditions Studied
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT Ricinoleic Acid 750 mg
- DIETARY_SUPPLEMENT Ricinoleic Acid 1500 mg
- DIETARY_SUPPLEMENT Ricinoleic Acid 3000 mg
Study Locations (1)
Minnesota
- Mayo Clinic Minnesota - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-01-08 |
| Est. Completion | 2024-07-31 |
| Phase | Early Phase 1 |
What the finished NCT06033222 record still lists
NCT06033222 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06033222 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06033222 about?
NCT06033222 is a clinical study titled "A Study of Perturbation of Human Small Intestinal Colonic Permeability". The purpose of this study is to evaluate the effect of castor oil versus placebo on intestinal permeability in healthy individuals.
What is the current status of trial NCT06033222?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2024-01-08. Estimated completion is 2024-07-31.
What conditions does trial NCT06033222 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT06033222?
The interventions under investigation include: Placebo (DRUG), Ricinoleic Acid 750 mg (DIETARY_SUPPLEMENT), Ricinoleic Acid 1500 mg (DIETARY_SUPPLEMENT), Ricinoleic Acid 3000 mg (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06033222?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06033222 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06033222's enrollment target sits among peer trials
24 791st of 1090 higher than 254 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
RECRUITING · Early Phase 1
-
SV2A Density Cannabis Use Disorder
RECRUITING · Early Phase 1
-
CBD-Microglia PET Study
RECRUITING · Early Phase 1
-
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Contrast Agent Kinetics and Safety: [18F]-Fluoromannitol
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI